This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT01167881 |
|---|---|
| Status | Completed |
| Phase | Phase 3 |
| Sponsor | Boehringer Ingelheim |
| Enrollment | 1,549 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Diabetes Mellitus, Type 2 |
| Interventions | BI 10773; Glimepiride; Placebo; Placebo |
| Start | Aug 2010 |
| Primary completion | Aug 2013 |
| Study completion | Aug 2015 |
| Results posted | Yes, in the registry |
| Registry last updated | Sep 2, 2016 |
| Collaborators | Eli Lilly and Company |
Compounds on this site that cite this trial
What the registry says the trial is about
This is a pivotal phase III study, mandatory to seek approval by regulatory authorities for BI 10773 as an anti-diabetic agent compared to an active comparator in patients with type 2 diabetes mellitus and insufficient glycaemic control.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| The Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 104 Weeks of Treatment. | Baseline and 104 weeks |
9 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 18, 2026. See the trial changes feed for what has changed recently.
More trials of ATX-304
More from Boehringer Ingelheim
- Survodutide: Phase 3 Trial in MASH (NCT06632457)
- Survodutide: Phase 3 Trial in MASH (NCT06632444)
- SYNCHRONIZE-MASLD: Survodutide, Phase 3 (NCT06309992)
- Survodutide: Phase 3 Trial (NCT06066528)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.